CA-ALTIUM-LLC
3.3.2020 05:02:07 CET | Business Wire | Press release
TASKING, the embedded software division of Altium (ASX:ALU), today announced its new multi-core development environment for third-generation AURIX™ microcontrollers from Infineon. This capability will allow TASKING and Infineon automotive customers to optimize performance for multi-core architecture for safety-critical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302006089/en/
“Infineon and TASKING have a longstanding relationship in expansion of software development tools for Tricore™/AURIX™,” said Ralf Ködel, Director Product Marketing Microcontroller at Infineon, “With this new environment, TASKING provides an innovative one-stop shop solution for our customers.”
This upcoming AURIX™ family of microcontrollers will be prepared for data-hungry automotive applications such as future gateways, domain and zone controllers, engine management, electro-mobility, and advanced driver assistance systems. At the same time these microcontrollers will deliver the safety features, throughput, and power-efficient performance necessary to meet increasing AI computational requirements.
The new TASKING development environment is being developed according to Automotive SPICE® Level 2 standards, with plans for TÜV certification according to ISO 26262 up to ASIL D. This development environment provides compiler support for the new Parallel Processing Unit (PPU) from Synopsys, one of the main enhancements in the next generation AURIX™ family of microcontrollers, in addition to all instruction set architectures used in the next generation AURIX™ TC v1.8.
“These new capabilities from TASKING, empower our automotive customers to make safer traditional and autonomous vehicles, by providing them with a more expansive set of software development tools,” said Franz Maidl, Director Global TASKING Business. “This expansion also reinforces our relationship with Infineon as a partner of choice for Tricore™/AURIX™.”
About TASKING
TASKING is the embedded software division of Altium (ASX:ALU). TASKING development tools are used by automotive manufacturers and the world's largest Tier 1 suppliers to develop embedded microcontroller-based powertrain, body control, and Advanced Driver-Assistance Systems (ADAS) - related applications for both traditional and electric vehicles. These customers and those from adjacent industries, rely on the TASKING development tools to create richer next-generation applications while achieving optimum reliability, safety, and performance.
ABOUT ALTIUM
Altium LLC (ASX:ALU), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302006089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom